Heroin-assisted treatment in the Netherlands: History, findings, and international context

European Neuropsychopharmacology

Volumn 20, Issue SUPPL. 2, 2010, Pages

  Blanken, Peter ^a,b   van den Brink, Wim ^a,c   Hendriks, Vincent M ^a,b   Huijsman, Ineke A ^a   Klous, Marjolein G ^d   Rook, Elisabeth J ^d,e   Wakelin, Jennifer S ^f   Barendrecht, Cas ^g   Beijnen, Jos H ^d   van Ree, Jan M ^a,h  

^a Central Committee on the Treatment of Heroin Addicts   (Netherlands)

^b Parnassia Addiction Research Center   (Netherlands)

^c UNIVERSITY OF AMSTERDAM   (Netherlands)

^d NETHERLANDS CANCER INSTITUTE   (Netherlands)

^e MEDICINES EVALUATION BOARD   (Netherlands)

^f Wakelin Alliance ^*  (Netherlands)

^g Addiction Research Institute Rotterdam   (Netherlands)

^h UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

Author keywords

Addiction treatment pharmacology; Drug dependence; Effectiveness; Heroin

Indexed keywords

AMPHETAMINE; BUPRENORPHINE; CAFFEINE; DEXTROMORAMIDE; DIAMORPHINE; HYDROMORPHONE; LEVACETYLMETHADOL; METHADONE; MORPHINE; OPIATE;

AGGRESSION; ARTICLE; CLINICAL EFFECTIVENESS; CLINICAL RESEARCH; CLINICAL TRIAL; COST EFFECTIVENESS ANALYSIS; DOSE RESPONSE; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG DEPENDENCE TREATMENT; DRUG EFFICACY; DRUG FORMULATION; DRUG MEGADOSE; DRUG METABOLISM; DRUG OVERDOSE; HEALTH PROGRAM; HEART ARRHYTHMIA; HEROIN DEPENDENCE; HUMAN; LEUKOENCEPHALOPATHY; LOW DRUG DOSE; METHADONE TREATMENT; METHODOLOGY; NETHERLANDS; OUTCOME ASSESSMENT; PATIENT COMPLIANCE; PHARMACODYNAMICS; PRESCRIPTION; PRIORITY JOURNAL; PSYCHOTHERAPY; REGISTRATION; SIDE EFFECT;

ADULT; COST-BENEFIT ANALYSIS; DRUG PRESCRIPTIONS; FEMALE; HEROIN; HEROIN DEPENDENCE; HISTORY, 20TH CENTURY; HISTORY, 21ST CENTURY; HUMANS; MALE; NARCOTICS; NETHERLANDS; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIALS AS TOPIC; TIME FACTORS; TREATMENT OUTCOME;

EID: 77950669889     PISSN: 0924977X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0924-977X(10)70001-8     Document Type: Article

References (196)

1. Ali R., Auriacombe M., Casas M., Cottler L., Farrell M., Kleiber D. Report of the external panel on the evaluation of the Swiss scientific studies of medically prescribed narcotics to drug addicts. Sucht 1999, 45:160-170.
2. American Psychiatric Association Diagnostic and Statistical Manual of mental disorders 1994, American Psychiatric Association, Washington, DC.
3. Back, S.E., Hartwell, K., Desantis, S.M., Saladin, M., McRae-Clark, A.L., Price, K.L., Moran-Santa Maria, M.M., Baker, N.L., Spratt, E., Kreek, M.J., Brady K.T., 2009. Reactivity to laboratory stress provocation predicts relapse to cocaine. Drug Alcohol Depend. August 31. [Epub ahead of print].
4. Bammer G., Van den Brink W., Gschwend P., Hendriks V., Rehm J. What can the Swiss and Dutch trials tell us about the potential risks associated with heroin prescribing?. Drug Alcohol Rev. 2003, 22:363-371.
5. Barber J.A., Thompson S.G. Analysis of cost data in randomized trials: an application of the non-parametric bootstrap. Stat. Med. 2000, 19:3219-3236.
6. Bieleman, B., Snippe, J., De Bie, E., 1995. Drugs binnen de grenzen, harddrugs en criminaliteit in Nederland; schattingen van de omvang. Intraval, Groningen/Rotterdam.
7. Blanken P., Hendriks V.M., Koeter M.W.J., Van Ree J.M., Van den Brink W. Matching of treatment-resistant heroin-dependent patients to medical prescription of heroin or oral methadone treatment: results from two randomized controlled trials. Addiction 2005, 100:89-95.
8. Blanken P., Hendriks V.M., Van Ree J.M., Van den Brink W. Outcome of long-term heroin-assisted treatment offered to chronic, treatment-resistant heroin addicts in the Netherlands. Addiction 2010, 105:300-308.
9. British Pharmacopoeia 2004, The Stationery Office, London.
10. Brooks R. EuroQol: the current state of play. Health Policy 1996, 37:53-72.
11. Buster M.C.A., Van Brussel G.H.A. Selectie van drugge-bruikers voor heroine experiment: Een vooronderzoek 1996, GG&GD Amsterdam, Amsterdam.
12. Buster M., Reurs H. Methadon verstrekking in Amsterdam 1997. Centrale Methadon Registratie 1998, GG&GD Amsterdam, Amsterdam.
13. Buster M., Rook L., Van Brussel G.H., Van Ree J.M., Van den Brink W. Chasing the dragon related to the impaired lung function among heroin users. Drug Alcohol Depend. 2002, 68:221-228.
14. Buster, M.C.A., Van den Brink, W., Van Brussel, G.H.A., Van Ree, J.M., 2010. Influence of treatment with inhalable heroin on pulmonary function (submitted).
15. Central Committee on the Treatment of Heroin Addicts (CCBH), 1997. Investigating the medical prescription of heroin. A randomized trial to evaluate the effectiveness of medically co-prescribed heroin and oral methadone, compared to oral methadone alone, in chronic, treatment-refractory heroin addicts. CCBH, Utrecht.
16. Central Committee on the Treatment of Heroin Addicts (CCBH), 2002. Medical co-prescription of heroin: two randomized controlled trials. CCBH, Utrecht.
17. Chang Y.J., Tsai C.H., Chen C.J. Leukoencephalopathy after inhalation of heroin vapor. J. Formos. Med. Assoc. 1997, 96:758-760.
18. Colom, J., Trujols, J., Cases, M., 2010. A randomized phase II pilot study comparing oral diacetylmorphine, oral morphine and methadone in heroin dependent inpatients: feasibility of double-blind clinical trials with oral diacetylmorphine (submitted).
19. Comer S.D., Collins E.D., MacArthur R.B., Fischman M.W. Comparison of intravenous and intranasal heroin self-administration by morphine-maintained humans. Psychophar-macology (Berl.) 1999, 143:327-338.
20. Crits-Christoph P., Siqueland L., Blaine J., Frank A., Luborsky L., Onken L.S., Muenz L.R., Thase M.E., Weiss R.D., Gastfriend D.R., Woody G.E., Barber J.P., Butler S.F., Daley D., Salloum I., Bishop S., Najavits L.M., Lis J., Mercer D., Griffin M.L., Moras K., Beck A.T. Psychosocial treatments for cocaine dependence: National Institute on Drug Abuse Collaborative Cocaine Treatment Study. Arch. Gen. Psychiatry 1999, 56:493-502.
21. D'Aunno T., Vaughn T.E. Variations in methadone treatment practices: results from a national study. JAMA 1992, 267:253-257.
22. DeFulio A., Donlin W.D., Wong C.J., Silverman K. Employment-based abstinence reinforcement as a maintenance intervention for the treatment of cocaine dependence: a randomized controlled trial. Addiction 2009, 104:1530-1538.
23. De la Fuente L., Saavedra P., Barrio G., Royuela L., Vicente J. Temporal and geographic variations in the characteristics of heroin seized in Spain and their relation with the route of administration. Spanish Group for the Study of the Purity of Seized Drugs. Drug Alcohol Depend 1996, 40:185-194.
24. Derks JT.M. De verstrekking van injecteerbare opiaten: Doelstelling van het morfine-verstrekkingsexperiment. Tijdschr. Sociale Gezondheidszorg 1984, 12:496-498.
25. Derks J.T.M. Het Amsterdamse morfine-verstrekkings-experiment 1990, Rijksuniversiteit Utrecht, Utrecht.
26. Derks J.T.M. The dispensing of injectable morphine in Amsterdam: experiences, results and implications for the Swiss project for the medical prescription of narcotics. The Medical Prescription of Narcotics: Scientific Foundations and Practical Experiences 1997, Hogrefe and Huber, Seattle, WA. M. Rihs-Middel (Ed.).
27. Derogatis, L.R., SCL-90: Administration, Scoring and Procedures. Manual II. Clinical Psychometric Research, Towsen, MD.
28. De Zwart W.M., van Wamel A.L. Jaarboek Verslaving 1997: Over gebruik en zorg in cijfers 1998, Bohn Stafleu van Loghum, Houten.
29. Dijkgraaf G.W., Van der Zanden B.P., De Borgie A.J.M., Blanken P., Van Ree J.M., Van den Brink W. Cost utility analysis of co-prescribed heroin compared with methadone maintenance treatment in heroin addicts in two randomised trials. Br. Med. J. 2005, 327:310.
30. Dole V.P., Nyswander M. A medical treatment for diacetylmorphine (heroin) addiction. A clinical trial with methadone hydrochloride. JAMA 1965, 193:646-650.
31. Driessen F.M.H.M. Methadonverstrekking in Nederland 1990, Bureau Driessen, Utrecht.
32. Driessen F.M.H.M. Methadoncliënten in Nederland 1992, Bureau Driessen, Utrecht.
33. Driessen F.M.H.M., Völker B.G.M., Kregting J., Van der Lelij B. De ontwikkeling van de situatie van methadoncliënten gedurende twee jaar 1999, Bureau Driessen, Utrecht.
34. Dutra L., Stathopoulou G., Basden S.L., Leyro T.M., Powers M.B., Otto M.W. A meta-analytic review of psychosocial interventions for substance use disorders. Am. J. Psychiatry 2008, 165:179-187.
35. EMCDDA, 2009a. Annual report on the state of the drugs problem in Europe, Publications Office of the European Union, Luxembourg (ISBN 978-92-9168-384-0).
36. EMCDDA, 2009b. Statistical Bulletin 2009, Publications Office of the European Union, Luxembourg.
37. European College of Neuropsychopharmacology Clinical relevance of response and improvement in psychopharmacology: a statement from the ECNP. Report of Consensus Meeting. Eur. Neuropsychopharmacol. 1995, 5:531-533.
38. Farrell M., Hall W. The Swiss heroin trials: testing alternative approaches. Br. Med. J. 1998, 316:639.
39. Faupel C.E. Drug availability, life structure, and situational ethics of heroin addict. Urban Life 1987, 15:395-419.
40. Ferri M., Davoli M., Perucci C.A. Heroin maintenance treatment for chronic heroin dependent individuals: a Cochrane systematic review of effectiveness. J Subst. Abuse Treat. 2006, 30:63-72.
41. Fischer B., Rehm J., Kirst M., Casas M., Hall W., Krausz M., Metrebian N., Reggers J., Uchtenhagen A., Van den Brink W., Van Ree J.M. Heroin-assisted treatment as a response to the public health problem of opiate dependence. Eur. J. Public Health 2002, 2:228-234.
42. Fischer B., Rehm J. Illicit opioid use and treatment for opioid dependence: challenges for Canada and beyond. Can. J. Psychiatry 2006, 51:621-623.
43. Fischer B., Oviedo-Joekes E., Blanken P., Haasen C., Rehm J., Schechter M.T., Strang J., Van den Brink W. Heroin-assisted treatment (HAT) a decade later: a brief update on science and politics. J. Urban Health 2007, 84:552-562.
44. Flock P. Pilot study to determine the effectiveness of diamorphine gel to control pressure ulcer pain. J. Pain Symptom Manage. 2003, 25:547-554.
45. Frei A. Economic evaluation of the Swiss project on medically prescribed heroin substitution treatment. Psychiatr. Prax. 2001, 28:S41-S44.
46. Frick U., Rehm J., Kovacic S., Ammann J., Uchtenhagen A. A prospective cohort study on orally administered heroin substitution for severely addicted opioid users. Addiction 2006, 101:1631-1639.
47. GGD Amsterdam Drugsproblematiek in Amsterdam 2007, GG&GD Amsterdam, Amsterdam.
48. Girardin F., Rentsch K.M., Schwab M.A., Maggiorini M., Pauli-Magnus C., Kullak-Ublick G.A., Meier P.J., Fattinger K. Pharmacokinetics of high doses of intramuscular and oral heroin in narcotic addicts. Clin. Pharmacol. Ther. 2003, 74:341-352.
49. Goldberger B.A., Darwin W.D., Grant T.M., Allen A.C., Caplan Y.H., Cone E.J. Measurement of heroin and its metabolites by isotope-dilution electron-impact mass spectrometry. Clin. Chem. 1993, 39:670-675.
50. Goldstein R.Z., Volkow N.D. Drug addiction and its underlying neurobiological basis: neuroimaging evidence for the involvement of the frontal cortex. Am. J. Psychiatry 2002, 159:1642-1652.
51. Goodman L.S., Gilman A.G. Goodman & Gilman's The Pharmacological Basis of Therapeutics 1996, McGraw-Hill, New York, NY. 9th edn.
52. Gopinathan C., Sockalingham I., Fung M.A., Peat S., Hanna M.H. A comparative study of patient-controlled epidural diamorphine, subcutaneous diamorphine and an epidural diamorphine/bupivacaine combination for postoperative pain. Eur. J. Anaesthesiol. 2000, 17:189-196.
53. Guttinger F., Gschwend P., Schulte B., Rehm J., Uchtenhagen A. Evaluating long-term effects of heroin-assisted treatment: the results of a 6-year follow-up. Eur. Addict. Res. 2003, 9:73-79.
54. Haasen C., Verthein U., Degkwitz P., Berger J., Krausz M., Naber D. Heroin-assisted treatment for opioid dependence: a randomised, controlled trial. Br. J. Psychiatry 2007, 191:55-62.
55. Haasen, C., Vertheim, U., Eiroa-Orosa, F.J., Schäfer, I., Reimer, J., 2010. Is heroin-assisted treatment effective for patients with no previous maintenance treatment? Results form the German randomized controlled trial. Eur. Addict. Res. (in press).
56. Halbsguth U., Rentsch K.M., Eich-Hochli D., Diterich I., Fattinger K. Oral diacetylmorphine (heroin) yields greater morphine bioavailability than oral morphine: bioavailability related to dosage and prior opioid exposure. Br. J. Clin. Pharmacol. 2008, 66:781-791.
57. Hallett A., O'Higgins F., Francis V., Cook T.M. Patient-controlled intranasal diamorphine for postoperative pain: an acceptability study. Anaesthesia 2000, 55:532-539.
58. Hallworth S.P., Fernando R., Bell R., Parry M.G., Lim G.H. Comparison of intrathecal and epidural diamorphine for elective caesarean section using a combined spinal-epidural technique. Br. J. Anaesth. 1999, 82:228-232.
59. Harding G. Patterns of heroin use: What do we know?. Br. J. Addict. 1988, 83:1247-1254.
60. Hartnoll R.L., Mitcheson M.C., Battersby A., Brown G., Ellis M., Fleming P., Hedley N. Evaluation of heroin maintenance in controlled trial. Arch. Gen. Psychiatry 1980, 37:877-884.
61. Hays S.E., Grady L.T., Kruegel A.V. Purity profiles for heroin, morphine, and morphine hydrochloride. J. Pharm. Sci. 1973, 62:1509-1513.
62. Hendriks V.M., Van den Brink W., Blanken P., Bosman I.J., Van Ree J.M. Heroin self-administration by means of " chasing the dragon": Pharmacodynamics and bioavailability of inhaled heroin. Eur. Neuropsychopharmacol. 2001, 11:241-252.
63. Hill M.D., Cooper P.W., Perry J.R. Chasing the dragon - neurological toxicity associated with inhalation of heroin vapour: case report. CMAJ 2000, 162:236-238.
64. Hoekstra M.J., Derks J. Verslaving, verslavingszorg en verslavingsbeleid in Nederland: een overzicht. Verslavingszorg, een vak apart 1991, NcGx, Utrecht. J. Derks, M. Hoekstra (Eds.).
65. Hogen Esch A.J., Van der Heide S., Van den Brink W., Van Ree J.M., Bruynzeel D.P., Coenraads P.J. Contact allergy and respiratory/mucosal complaints from heroin (diacetylmorphine). Contact Dermat. 2006, 54:42-49.
66. Hosmer D.W., Lemeshow S. Applied Logistic Regression 2000, John Wiley, New York, NY.
67. Huizer H. Analytical studies on illicit heroin. V. Efficacy Heroin-assisted treatment in the Netherlands: History, findings, and international context of volatilization during heroin smoking. Pharm Weekbl Sci 1987, 9:203-211.
68. Hull C.L. Principles of Behavior 1943, Appleton-Century-Crofts, New York, NY.
69. Inturrisi C.E., Max M.B., Foley K.M., Schultz M., Shin S.U., Houde R.W. The pharmacokinetics of heroin in patients with chronic pain. N. Engl. J. Med. 1984, 310:1213-1217.
70. Inturrisi C.E., Schultz M., Shin S., Umans J.G., Angel L., Simon E.J. Evidence from opiate binding studies that heroin acts through its metabolites. Life Sci. 1983, 33(Suppl. 1):773-776.
71. Judson B.A., Goldstein A. Prediction of long-term outcome for heroin addicts admitted to a methadone maintenance program. Drug Alcohol Depend 1982, 10:383-391.
72. Kaa E., Bent K. Impurities, adulterants and diluents of illicit heroin in Denmark (Jutland and Funen). Forensic Sci. Int. 1986, 31:195-210.
73. Kahan M., Srivastava A., Shen K. Why we object to NAOMI. Heroin maintenance in Canada. Can. Fam. Physician 2006, 52:709-711.
74. Kamendulis L.M., Brzezinski M.R., Pindel E.V., Bosron W.F., Dean R.A. Metabolism of cocaine and heroin is catalyzed by the same human liver carboxylesterases. J. Pharmacol. Exp. Ther. 1996, 279:713-717.
75. Kendall J.M., Latter V.S. Intranasal diamorphine as an alternative to intramuscular morphine: pharmacokinetic and pharmacodynamic aspects. Clin. Pharmacokinet. 2003, 42:501-513.
76. Kendall J.M., Reeves B.C., Latter V.S. Multicentre randomised controlled trial of nasal diamorphine for analgesia in children and teenagers with clinical fractures. BMJ 2001, 322:261-265.
77. Klous, M.G., 2004a. Development of diacetylmorphine preparations for prescription to opioid dependent patients. Universiteit Utrecht, Utrecht (ISBN: 90-393-3836-1).
78. Klous M.G., Bronner G.M., Nuijen B., Van Ree J.M., Beijnen J.H. Pharmaceutical heroin for inhalation: Thermal analysis and recovery experiments after volatilisation. J. Pharm. Biomed. Anal. 2005, 39:944-950.
79. Klous M.G., Lee W.C., Hillebrand M.J.X., Van den Brink W., Van Ree J.M., Beijnen J.H. Analysis of diacetylmorphine, caffeine and degradation products after volatilisation of pharmaceutical heroin for inhalation. J. Anal. Toxicol. 2006, 30:6-13.
80. Klous M.G., Lee W.C., Van den Brink W., Van Ree J.M., Beijnen J.H. Volatilisation of diacetylmorphine: in vitro simulation of " chasing the dragon" Pharmazie 2006, 61:438-445.
81. Klous M.G., Nuijen B., Van den Brink W., Van Ree J.M., Beijnen J.H. Development and manufacture of diacetylmorphine/caffeine sachets for inhalation via 'chasing the dragon' by heroin addicts. Drug Dev. Ind. Pharm. 2004, 30:775-784.
82. Klous M.G., Nuijen B., Van den Brink W., Van Ree J.M., Beijnen J.H. Pharmaceutical development of an intravenous dosage form of diacetylmorphine hydrochloride. PDA J. Pharm. Sci. Technol. 2004, 58:287-295.
83. Klous M.G., Nuijen B., Van den Brink W., Van Ree J.M., Beijnen J.H. Process characterisation, optimisation and validation of production of diacetylmorphine/caffeine sachets: a design of experiments approach. Int. J. Pharm. 2004, 285:65-75.
84. Klous M.G., Rook E.J., Hillebrand M.J.X., Van den Brink W., Van Ree J.M., Beijnen J.H. Deuterodiacetylmorphine as a marker for use of illicit heroin by addicts in a heroin-assisted treatment program. J. Anal. Toxicol. 2005, 29:564-569.
85. Klous M.G., Van den Brink W., Van Ree J.M., Beijnen J.H. Development of pharmaceutical heroin preparations for medical co-prescription to opioid dependent patients. Drug Alcohol Depend. 2005, 80:283-295.
86. Kokkevi A., Hartgers C. EuropASI: European adaptation of a multidimensional assessment instrument for drug and alcohol dependence. Eur. Addict. Res. 1995, 1:208-210.
87. Korrelboom, K., Ten Broek, E., 2004. Geïntegreerde cognitivie gedragstherapie [Integrated cognitive behavioural therapy]. Coutinho, Muiderberg.
88. Kokkevi A., Hartgers C. EuropASI: European adaptation of a multidimensional assessment instrument for drug and alcohol dependence. Eur. Addict. Res. 1995, 1:208-210.
89. Korf D.J. Dutch treat: formal control and illicit drug use in the Netherlands 1995, Thesis Publishers, Amsterdam.
90. Korf D.J., Lettink D., Bouma H. Methadondosering in Nederland: Een exploratief onderzoek verstrekkers en clienten naar hoge en lage doseringen methadon 1998, Bureau voor Onderzoek en Statistiek, Amsterdam.
91. Kreek M.J. Methadone-related opioid agonist pharma-cotherapy for heroin addiction. History, recent molecular and neurochemical research and future in mainstream medicine. Ann. N.Y. Acad. Sci. 2000, 909:186-216.
92. Kuhn J., Lenartz D., Huff W., Lee S., Koulousakis A., Klosterkoetter J., Sturm V. Remission of alcohol dependency following deep brain stimulation of the nucleus accumbens: valuable therapeutic implications?. J. Neurol. Neurosurg. Psychiatry 2007, 78:1152-1153.
93. LADIS Methadone clients in addiction care in the Netherlands (1994-2002) 2004, Stichting IVZ, Houten.
94. Leshner A.I. Addiction is a brain disease, and it matters. Science 1997, 278:45-47.
95. Lintzeris N., Strang J., Metrebian N., Byford S., Hallam C., Lee S., Zador D. Methodology for the Randomised Injecting Opioid Treatment Trial (RIOTT): evaluating injectable methadone and injectable heroin treatment versus optimised oral methadone treatment in the UK. Harm Reduct. J. 2006, 3:28.
96. Lockridge O., Mottershaw-Jackson N., Eckerson H.W., La Du B.N. Hydrolysis of diacetylmorphine (heroin) by human serum cholinesterase. J. Pharmacol. Exp. Ther. 1980, 215:1-8.
97. Magura S., Nwakeze P.C., Demsky S.Y. Pre-and in-treatment predictors of retention in methadone treatment using survival analysis. Addiction 1998, 93:51-60.
98. Mantione M., Van den Brink W., Schuurman P.R., Denys D. Smoking cessation and weight loss after chronic deep brain stimulation of the nucleus accumbens: therapeutic and research implications: case report. Neurosurgery 2010, 66:E218.
99. March J.C., Oviedo-Joekes E., Perea-Milla E., Carrasco F. Controlled trial of prescribed heroin in the treatment of opioid addiction. J. Subst. Abuse Treat. 2006, 31:203-211.
100. Marissen M.A., Franken I.H., Waters A.J., Blanken P., Van den Brink W., Hendriks V.M. Attentional bias predicts heroin relapse following treatment. Addiction 2006, 101:1306-1312.
101. Marsden J., Gossop M., Stewart D., Best D., Farrell M., Lehmann P., et al. The Maudsley addiction profile (MAP): a brief instrument for assessing treatment outcome. Addiction 1998, 93:1857-1867.
102. Martindale: The Complete Drug Reference, Electronic version. 2009. Pharmaceutical Press, London.
103. Masters N., Heap G., Wedly J., Moore A. Inhaled nebulised morphine and diamorphine: useful in general practice?. Practitioner 1988, 232:910-914.
104. McCusker C., Davies M. Prescribing drug of choice to illicit heroin users: the experience of a U.K. community drug team. J. Subst. Abuse Treat. 1996, 13:521-531.
105. McCoubrie R., Jeffrey D. Intravesical diamorphine for bladder spasm. J. Pain Symptom Manage. 2003, 25:1-3.
106. Medicines Evaluation Board (MEB), 2006. Public Assessment Report: Diacetylmorfine 75/100/150/200 mg, poeder voor inhalatiedamp en Diacetylmorfine HCl 3 gram, poeder voor oplossing voor injectie, RVG 33463, 33464, 33465, 33466, 33467 edn. Medicines Evaluation Board, Den Haag.
107. Medicines Evaluation Board, 2007, Public Assessment Report " Diacetylmorphine and Diacetylmorphine HCl" MEB, The Hague. http://db.cbg-meb.nl/Pars/h33463.
108. MHRA, 2008. Public Assessment Report: Diamorphine hydrochloride BP 100 mg and 500 mg lyophilisate for solution for injection, PL 30956/0001-2 edn. Medicines and Healthcare Products Regulatory Agency, London.
109. Metrebian N., Shanahan W., Wells B., Stimson G.V. Feasibility of prescribing injectable heroin and methadone to opiate-dependent drug users: associated health gains and harm reductions. Med. J. Aust. 1998, 168:596-600.
110. Metrebian N., Carnwath T., Stimson G.V., Storz T. Survey of doctors prescribing diamorphine (heroin) to opiate-dependent drug users in the United Kingdom. Addiction 2002, 97:1155-1161.
111. Metrebian N., Carnwath Z., Mott J., Carnwath T., Stimson G.V., Sell L. Patients receiving a prescription for diamorphine (heroin) in the United Kingdom. Drug Alcohol Rev. 2006, 25:115-121.
112. Mitcheson M. Drug clinics in the 1970s. Heroin Addiction and Drug Policy: The British System 1994, Oxford University Press, Oxford. J. Strang, M. Gossop (Eds.).
113. Miller W.R. Motivational interviewing: research, practice, and puzzles. Addict. Behav. 1996, 21:835-842.
114. Miller W.R., Rose G.S. Toward a theory of motivational interviewing. Am. Psychol. 2009, 64:527-537.
115. Mo B.P., Way E.L. An assessment of inhalation as a mode of administration of heroin by addicts. J. Pharmacol. Exp. Ther. 1966, 154:142-151.
116. Moffat A.C., Jackson J.V., Moss M.S., Widdop B. Clarke's isolation and identification of drugs 1986, The Pharmaceutical Press, London. 2nd edn.
117. Morgan M. The rational use of intrathecal and extradural opioids. Br. J. Anaesth 1989, 63:165-188.
118. National Drug Monitor Drug situation 2006 2007, 185. Trimbos Instituut, Utrecht.
119. Nationale Drug Monitor, 2001. Jaarbericht 2001 [Annual Report 2001]. Trimbos Instituut, Utrecht.
120. Nationale Drug Monitor, 2008. Jaarbericht 2007 [Annual Report 2007]. Trimbos Instituut, Utrecht. Netherlands Health Council: Committee on Pharmacological Interventions in Heroin Addicts (1995). The presciption of heroin to heroin addicts. Netherlands Health Council, The Hague (publication no. 1995/12E).
121. O'Brien C.P. Neuroplasticity in addictive disorders. Dialogues Clin. Neurosci. 2009, 11:350-353.
122. O'Doherty C.A., Hall E.J., Schofield L., Zeppetella G. Drugs and syringe drivers: a survey of adult specialist palliative care practice in the United Kingdom and Eire. Palliat. Med. 2001, 15:149-154.
123. Office of National Drug Control Policy (ONDCP) National drug control strategy http://www.whitehousedrugpolicy.gov.
124. Oldendorf W.H., Hyman S., Braun L., Oldendorf S.Z. Blood-brain barrier: penetration of morphine, codeine, heroin, and methadone after carotid injection. Science 1972, 178:984-986.
125. Ooteman W., Naassila M., Koeter M.W., Verheul R., Schippers G.M., Houchi H., Daoust M., Van den Brink W. Predicting the effect of naltrexone and acamprosate in alcohol-dependent patients using genetic indicators. Addict. Biol. 2009, 14:328-337.
126. Ooteman W., Verheul R., Naassila M.l., Daoust M., Schippers G.M., Koeter M.W.J., Van den Brink W. Patient-treatment matching with anti-craving medications in alcohol-dependent patients: A review on phenotypic, endophenotypic and genetic indicators. J. Subst. Use 2005, 10:75-96.
127. Oslin D.W., Berrettini W., Kranzler H.R., Pettinati H., Gelernter J., Volpicelli J.R., O'Brien C.P. A functional polymorphism of the mu-opioid receptor gene is associated with naltrexone response in alcohol-dependent patients. Neuropsychopharmacology 2003, 28:1546-1552.
128. Oviedo-Joekes E., Brissette S., Marsh D.C., Lauzon P., Guh D., Anis A., Schechter M.T. Diacetylmorphine versus methadone for the treatment of opioid addiction. N. Engl. J. Med. 2009, 361:777-786.
129. Oviedo-Joekes E., Nosyk B., Marsh D.C., Guh D., Brissette S., Gartry C., Krausz M., Anis A., Schechter M.T. Scientific and political challenges in North America's first randomized controlled trial of heroin-assisted treatment for severe heroin addiction: rationale and design of the NAOMI study. Clin. Trials 2009, 6:261-271.
130. Parrino M.W. State Methadone Maintenance Treatment Guidelines 1992, Department of Health and Human Services, Center for Substance Abuse Treatment, Rockville, MD.
131. Perea-Milla E., Ayçaguer L.C., Cerdà J.C., Saiz F.G., Rivas-Ruiz F., Danet A., Vallecillo M.R., Oviedo-Joekes E. Efficacy of prescribed injectable diacetylmorphine in the Andalusian trial: Bayesian analysis of responders and non-responders according to a multi domain outcome index. Trials 2009, 10:70.
132. Perger L., Rentsch K.M., Kullak-Ublick G.A., Verotta D., Fattinger K. Oral heroin in opioid-dependent patients: pharmacokinetic comparison of immediate and extended release tablets. Eur. J. Pharm. Sci. 2009, 36:421-432.
133. Perneger T.V., Giner F., Del Rio M., Mino A. Randomised trial of heroin maintenance programme for addicts who fail in conventional drug treatments. BMJ 1998, 317:8-13.
134. Petry N.M., Alessi S.M., Carroll K.M., Hanson T., MacKinnon S., Rounsaville B., Sierra S. Contingency management treatments: Reinforcing abstinence versus adherence with goal-related activities. J. Consult. Clin. Psychol. 2006, 74:592-601.
135. Poochikian G.K., Cradock J.C. Stability of Brompton mixtures: determination of heroin (diacetylmorphine) and cocaine in presence of their hydrolysis products. J. Pharm. Sci. 1980, 69:637-639.
136. Project MATCH Research Group Matching alcoholism treatments to client heterogeneity: Project MATCH posttreatment drinking outcomes. J. Stud. Alcohol 1997, 58:7-29.
137. Rehm J., Gschwend P., Steffen T., Gutzwiller F., Dobbler-Mikola A., Uchtenhagen A. Feasibility, safety, and efficacy of injectable heroin prescription for refractory opioid addicts: a follow-up study. Lancet 2001, 358:1417-1420.
138. Rehm J., Van den Brink W. 15 years of research on prescribed heroin: How do the results of the German heroin trial fit into the puzzle of the Swiss and Dutch results?. Sucht 2007, 53:262-264.
139. Risser D., Uhl A., Stichenwirth M., Honigschnabl S., Hirz W., Schneider B., Stellwag-Carion C., Klupp N., Vycudilik W., Bauer G. Quality of heroin and heroin-related deaths from 1987 to 1995 in Vienna, Austria. Addiction 2000, 95:375-382.
140. Rogers R.E., Higgins S.T., Silverman K., Thomas C.S., Badger G.J., Bigelow G., Stitzer M. Abstinence-contingent reinforcement and engagement in non-drug-related activities amongillicitdrugabusers. Psychol. Addict. Behav. 2008, 22:544-550.
141. Rook, E.J. (2004) Pharmacokinetics and pharmacodynamics of diacetylmorphine in opioid dependent patients. Universiteit Utrecht, Utrecht (ISBN: 90-6464-7992).
142. Rook E.J., Huitema A.D.R., Van den Brink W., Van Ree J.M., Beijnen J.H. Population pharmacokinetics of heroin and its major metabolites. Clin. Pharmacokinet. 2006, 45:401-417.
143. Rook E.J., Van Ree J.M., Van den Brink W., Hillebrand M.J.X., Huitema A.D.R., Hendriks V.M., Beijnen J.H. Pharmacokinetics and pharmacodynamics of high doses of pharmaceutically prepared heroin, by intravenous or by inhalation route, in opioid dependent patients. Basic Clin. Pharmacol. Toxicol. 2006, 98:86-96.
144. Rook E.J., Van Zanten A.P., Van den Brink W., Van Ree J.M., Beijnen J.H. Mast cell mediator tryptase levels after inhalation or intravenous administration of high doses of pharma-ceutically prepared heroin. Drug Alcohol Depend. 2006, 85:185-190.
145. Rook E.J., Huitema A.D., Vanden Brink W., Hillebrand M.J., Van Ree J.M., Beijnen J.H. Screening for illicit heroin Heroin-assisted treatment in the Netherlands: History, findings, and international context use in patients in a heroin-assisted treatment program. J. Anal. Toxicol. 2006, 30:390-394.
146. Rook E.J., Huitema A.D., Van den Brink W., Van Ree J.M., Beijnen J.H. Pharmacokinetics and pharmacokinetic variability of heroin and its metabolites: review of the literature. Curr. Clin. Pharmacol. 2006, 1:109-118.
147. Salmon A.Y., Goren Z., Avissar Y., Soreq H. Human erythrocyte but not brain acetylcholinesterase hydrolyses heroin to morphine. Clin. Exp. Pharmacol. Physiol. 1999, 26:596-600.
148. Sanders J.C. Paediatric regional anaesthesia, a survey of practice in the United Kingdom. Br. J. Anaesth. 2002, 89:707-710.
149. Schechter MT. NAOMI - her time has come. North American Opiate Medication Initiative. J. Urban Health 2002, 79:164-165.
150. Schechter M. North American Opiate Medication Initiative (NAOMI): Multi-Centre, Randomized Controlled Trial of Heroin-Assisted Therapy for Treatment-Resistant Injection Opiate Users 2006, Canadian Institutes of Health Research, Canada.
151. Schreuder, R.F, and Broex, V.M.F., 1998. Verkenning drugsbeleid in Nederland: feiten, opinies en scenario's. STG, Zoetermeer.
152. Schulenburg J., Claes C. Gesundheitsökonomische Begleit-forschung und Spezialstudie im Rahmen des bundesdeutschen Modellprojekts zur kontrollierten Heroinvergabe an Schwerstab-hängige http://www.heroinstudie.de/Gesundheitsoekonomie.
153. Selley D.E., Cao C.C., Sexton T., Schwegel J.A., Martin T.J., Childers S.R. Mu opioid receptor-mediated G-protein activation by heroin metabolites: evidence for greater efficacy of 6-monoacetylmorphine compared with morphine. Biochem. Pharmacol. 2001, 62:447-455.
154. Stelten B.M., Noblesse L.H., Ackermans L., Temel Y., Visser-Vandewalle V. The neurosurgical treatment of addiction. Neurosurg. Focus 2008, 25:E5.
155. Sneader W. The discovery of heroin. Lancet 1998, 352:1697-1699.
156. Stalder A.B. Heroin-Zigaretten. In vitro-und in vivo-Rauchstudien 1997, Universität Bern, Bern.
157. Stotts A.L., Mooney M.E., Sayre S.L., Novy M., Schmitz J.M., Grabowski J. Illusory predictors: Generalizability of findings in cocaine treatment retention research. Addict. Behav. 2007, 32:2819-2836.
158. Strang J., Ruben S., Farrell M., Gossop M. Prescribing heroin and other injectable drugs. Heroin Addiction and Drug Policy: The British System 1994, Oxford University Press, Oxford. J. Strang, M. Gossop (Eds.).
159. Strang J., Griffiths P., Gossop M. Heroin in the UK: Different forms, different origins, and the relationship to different routes of administration. Drug Alcohol Rev. 1997, 16:329-337.
160. Strang J., Marsden J., Cummins M., Farrell M., Finch E., Gossop M., Stewart D., Welch S. Randomized trial of supervised injectable versus oral methadone maintenance: report of feasibility and 6-month outcome. Addiction 2000, 95:1631-1645.
161. Strang, J., Metrebian, N., Lintzeris, N., Potts, L., Carnwath, T., Mayet, S., Williams, H., Zador, D., Evers, R., Groshkova, T., Charles, V., Martin, A., Forzisi, L., 2010. Heroin on trial: the RIOTT randomised trial of supervised injectable heroin and injectable methadone as treatment for chronic heroin addicts persistently failing in orthodox treatment. Lancet (in press).
162. The Merck Index, 12th edn. Merck, Whitehouse Station, NJ.
163. Trujols J., Iraurgi I. Political challenges in randomized controlled trials of heroin-assisted treatment for severe heroin addiction: a Spanish experience. Clin. Trials 2009, 6:658-659.
164. Uchtenhagen A. Diversified prescription of narcotics to heroin addicts. Basis, design, research plan. Schweiz Rundsch. Med. Prax. 1994, 83:931-936.
165. Uchtenhagen A., Gutzwiller F., Dobler-Mikola A., Blatter R. Program for a medical prescription of narcotics, interim report of the research representatives 1996, University of Zürich, Zürich.
166. Uchtenhagen A., Gutzwiller F., Dobler-Mikola A. Versuche für eine ärtzliche Verschreibung von Betäubungsmitteln: Zweiter Zwischenbericht der Forschungsbeauftragten 1996, Institut für Suchtforschung in Verbinding mit der Universität Zürich, Zürich.
167. Uchtenhagen A., Gutzwiller F., Dobler-Mikola A. Versuche für eine ärtzliche Verschreibung von Betäubungsmitteln: Abschluss-bericht der Forschungsbeauftragten 1997, Institute für Suchtforschung in Verbinding mit der Universität Zürich, Zürich.
168. Uchtenhagen, A., Dobler-Mikola, A., Steffen, T., Gutzwiller, F., Blattler, R., Pfeiffer, S., 1999. Prescription of Narcotics for Heroin Addicts: Main Results of the Swiss National Cohort Study. Medical Prescription of Narcotics, Vol. 1. Karger, Basel.
169. Uchtenhagen, A., 2009. Heroin-assisted treatment in Switzerland: a case study in policy change. Addiction November 17 [Epub ahead of print].
170. Van Brussel G.H.A. Evaluatieverslag Palfium behandeling voor langdurig heroïneverslaafden 1995, GG&GD Amsterdam, Amsterdam.
171. Van Brussel G.H.A. The morphine distribution program in Amsterdam: practical experiences. The medical prescription of narcotics: scientific foundations and practical experiences 1997, Hogrefe and Huber, Seattle, WA. M. Rihs-Middel (Ed.).
172. Van Brussel G.H.A., Buster M.C.A., Van der Woude D.H. Dovend vuur: jaarbericht drugsafdeling 1994-1995 1996, GG&GD Amsterdam, Amsterdam.
173. Van den Brink W., Hendriks V.M., Van Ree J.M. Medical co-prescription of heroin to chronic, treatment-resistant methadone patients in the Netherlands. J. Drug Issues 1999, 29(3):587-608.
174. Van den Brink W., Hendriks V.M., Blanken P., Koeter M.W.J., Van Zwieten B.J., Van Ree J.M. Medical prescription of heroin to treatment resistant heroin addicts: two randomised controlled trials. Br. Med. J. 2003, 330:1297.
175. Van den Brink W., Haasen C. Evidence-based treatment of opioid-dependent patients. Can. J. Psychiatry 2006, 51:635-646.
176. Van den Brink W. Heroin assisted treatment. BMJ 2009, 339:b4545.
177. Van der Lelij B., Driessen F.M.H.M. Psychosociale hulpverlening voor de doelgroep van het heroïneverstrekkings-experiment 1998, Bureau Driessen, Utrecht.
178. Van der Zanden B.P., Dijkgraaf M.G.W. Type, frequency, and costs of illegal activities by heroin addicts in the Netherlands who are eligible for medical coprescription of heroin. Internal report 2004, Academic Medical Centre, Department of Clinical Epidemiology and Biostatistics, Amsterdam.
179. Van der Zanden B.P., Dijkgraaf M.G., Blanken P., De Borgie C.A., Van Ree J.M., Van den Brink W. Validity of the EQ-5D as a generic health outcome instrument in a heroin-dependent population. Drug Alcohol Depend 2006, 82:111-118.
180. Van der Zanden B.P., Dijkgraaf M.G., Blanken P., Van Ree J.M., Van den Brink W. Patterns of acquisitive crime during methadone maintenance treatment among patients eligible for heroin assisted treatment. Drug Alcohol Depend. 2007, 86:84-90.
181. Van Gageldonk A., De Zwart W., Van der Stel J., Donker M. De Nederlandse verslavingszorg: overzicht van de kennis over aanbod, vraag en effect 1997, Trimbos Instituut, Utrecht.
182. Van Ree J.M., Slangen J.L., De Wied D. Intravenous self-administration of drugs in rats. J. Pharmacol. Exp. Ther. 1978, 204:547-557.
183. Van Ree J.M., Gerrits M.A., Vanderschuren L.J. Opioids, reward and addiction: An encounter of biology, psychology, and medicine. Pharmacoll Rev. 1999, 51:341-396.
184. Verthein U., Bonorden-Kleij K., Degkwitz P., Dilg C., Köhler W.K., Passie T., Soyka M., Tanger S., Vogel M., Haasen C. Long-term effects of heroin-assisted treatment in Germany. Addiction 2008, 103:960-966.
185. Ward M., Minto G., Alexander-Williams J.M. A comparison of patient-controlled analgesia administered by the intravenous or intranasal route during the early postoperative period. Anaesthesia 2002, 57:48-52.
186. Weinberg D.S., Inturrisi C.E., Reidenberg B., Moulin D.E., Nip T.J., Wallenstein S., Houde R.W., Foley K.M. Sublingual absorption of selected opioid analgesics. Clin. Pharmacol. Ther. 1988, 44:335-342.
187. Wilson J.A., Kendall J.M., Cornelius P. Intranasal diamorphine for paediatric analgesia: assessment of safety and efficacy. J. Accid. Emerg. Med. 1997, 14:70-72.
188. Wolters E.C., Van Wijngaarden G.K., Stam F.C., Rengelink H., Lousberg R.J., Schipper M.E., Verbeeten B. Leucoencephalopathy after inhaling " heroin" pyrolysate. Lancet 1982, 2:1233-1237.
189. Wodak A. Public health and politics: the demise of the ACT heroin trial. Med. J. Aust. 1997, 167:348-349.
190. World Health Organization (WHO) Guidelines for the Psychosocially Assisted Pharmacological Treatment of Opioid Dependence 2009, WHO, Geneva.
191. Yeh S.Y., Gorodetzky C.W., Krebs H.A. Isolation and identification of morphine 3-and 6-glucuronides, morphine 3,6-diglucuronide, morphine 3-ethereal sulfate, normorphine, and normorphine 6-glucuronide as morphine metabolites in humans. J. Pharm. Sci. 1977, 66:1288-1293.
192. Yeh S.Y., McQuinn R.L., Gorodetzky C.W. Identification of diacetylmorphine metabolites in humans. J. Pharm. Sci. 1977, 66:201-204.
193. Zelen M. A new design for randomized controlled trials. N. Engl. J. Med. 1979, 300:1242-1245.
194. Zelen M. Randomized consent designs for clinical trials: an update. Stat. Med. 1990, 9:645-646.
195. Zinberg N.E. Drug, set, and setting: The basis for controlled intoxicant use 1984, Yale University Press, New Haven, CT.
196. Zinberg N.E., Harding W.M., Stelmack S.M. Patterns of heroin use. Ann. N.Y. Acad. Sci. 1978, 311:10-24.